Editor's Picks
Editor's Picks
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Sees Promising Future with FDA Approval
March 18, 2026Kanzhun Limited (BOSS Zhipin) Financial Overview
March 18, 2026Earnings per Share (EPS) of $0.27, slightly below estimates. Revenue reported at approximately $297.1 million, missing estimates. Financial Health indicated by a low debt-to-equity ratio and a strong current ratio....
Editor's Picks
Ovid Therapeutics Beats Q4 Earnings and Revenue Forecasts
March 18, 2026We will not share your information & you can unsubscribe at any time. You agree to our terms of service & privacy policy. You agree to receive emails & correspondence from Nextmemealert.
